GH Research PLC
Business
GH Research is a clinical-stage biopharmaceutical company developing novel mebufotenin therapies for treatment-resistant depression and other psychiatric and neurological disorders. The company's lead product candidate, GH001, is an inhalable mebufotenin formulation; its second candidate, GH002, is formulated for intravenous administration. GH Research is advancing GH001 through clinical development with completed Phase 2b trials in treatment-resistant depression and Phase 2a trials in bipolar II disorder and postpartum depression, while developing a proprietary aerosol delivery device. The company intends to commercialize its product candidates in the United States and major European markets, either independently or through strategic partnerships.
Summary from 20-F filed 2026-03-05
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-48.26M |
| Total assets | $288.23M |
| Total liabilities | $8.53M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GH Research PLC's CIK number?
GH Research PLC's SEC CIK number is 0001855129 (1855129). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GH Research PLC's SEC filings?
All of GH Research PLC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.